Chemical Structure
Chemical Structure
Genistein [446-72-0]
AG-CN2-0427
Overview
- SupplierAdipoGen Life Sciences
- Product NameGenistein [446-72-0]
- Delivery Days Customer10
- CAS Number446-72-0
- CertificationResearch Use Only
- Estimated Purity>99%
- Hazard InformationWarning
- Molecular FormulaC15H10O5
- Molecular Weight270.2
- Scientific DescriptionCell-permeable, reversible, substrate competitive tyrosine kinase inhibitor (including EGFR phosphorylation), implicated in almost all cell growth and proliferation signal cascades [1]. Inhibitor of mammalian DNA topoisomerase II [2]. Anticancer agent, inducing cell cycle arrest and apoptosis [3]. Antiangiogenic agent, down-regulates the transcription of genes involved in controlling angiogenesis [12]. Binds estrogen receptor beta. Can increase the rate of growth of some ER expressing breast cancers [4, 10]. Potent alpha-glucosidase inhibitor [5]. Anthelmintic [6]. Anti-diabetic. Activates nuclear receptors, oestrogen receptors and peroxisome proliferator-activated receptors (all PPAR isoforms) and it inhibits various enzyme activities [7, 8, 14]. Inhibitor of GLUT4-mediated glucose uptake in 3T3-L1 adipocytes [9]. Stimulator of autophagy vacuolization [12]. Antioxidant [13]. TRAIL sensitizer [15]. Acts as an agonist at the GPR30 receptor [16]. MALT1 inhibitor [17] DNA methyltransferase inhibitor [18]. Genistein exhibits synergistic antibacterial effects on MRSA [19]. - Chemical. CAS: 446-72-0. Formula: C15H10O5. MW: 270.2. Synthetic. Cell-permeable, reversible, substrate competitive tyrosine kinase inhibitor (including EGFR phosphorylation), implicated in almost all cell growth and proliferation signal cascades. Inhibitor of mammalian DNA topoisomerase II. Anticancer agent, inducing cell cycle arrest and apoptosis. Antiangiogenic agent, down-regulates the transcription of genes involved in controlling angiogenesis. Binds estrogen receptor beta. Can increase the rate of growth of some ER expressing breast cancers. Potent alpha-glucosidase inhibitor. Anthelmintic. Anti-diabetic. Activates nuclear receptors, oestrogen receptors and peroxisome proliferator-activated receptors (all PPAR isoforms) and it inhibits various enzyme activities. Inhibitor of GLUT4-mediated glucose uptake in 3T3-L1 adipocytes. Stimulator of autophagy vacuolization. Antioxidant. TRAIL sensitizer. Acts as an agonist at the GPR30 receptor. MALT1 inhibitor DNA methyltransferase inhibitor. Genistein exhibits synergistic antibacterial effects on MRSA.
- SMILESOC1=CC=C(C=C1)C1=COC2=CC(O)=CC(O)=C2C1=O
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352200
References
- Genistein, a specific inhibitor of tyrosine-specific protein kinases: T. Akiyama, et al.; J. Biol. Chem. 262, 5592 (1987)
- Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II: J. Markovits, et al.; Cancer Res. 49, 5111 (1989)
- Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene: G. Peterson & S. Barnes; BBRC 179, 661 (1991)
- Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta: G.G. Kuiper, et al.; Endocrinology 139, 4252 (1998)
- Genistein, a soy isoflavone, is a potent alpha-glucosidase inhibitor: DS. Lee & SH. Lee; FEBS Lett. 501, 84 (2001)
- Anthelmintic efficacy of Flemingia vestita: genistein-induced effect on the activity of nitric oxide synthase and nitric oxide in the trematode parasite, Fasciolopsis buski: P.K. Kar, et al.; Parasitol. Int. 51, 249 (2002)
- Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells: O. Mezei, et al.; J. Nutr. 133, 1238 (2003)
- Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein: Z.C. Dang, et al.; J. Biol. Chem. 278, 962 (2003)
- Genistein directly inhibits GLUT4-mediated glucose uptake in 3T3-L1 adipocytes: M. Bazuine, et al.; BBRC 326, 511 (2005)
- Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations Y.H. Ju, et al.; Carcinogenesis 27, 1292 (2006)